450 related articles for article (PubMed ID: 27476094)
1. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
[TBL] [Abstract][Full Text] [Related]
2. Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease.
Diletti R; Ishibashi Y; Felix C; Onuma Y; Nakatani S; van Mieghem NM; Regar E; Valgimigli M; de Jaegere PP; van Ditzhuijzen N; Fam JM; Ligthart JMR; Lenzen MJ; Serruys PW; Zijlstra F; Jan van Geuns R
Catheter Cardiovasc Interv; 2017 Jul; 90(1):58-69. PubMed ID: 27896897
[TBL] [Abstract][Full Text] [Related]
3. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
[TBL] [Abstract][Full Text] [Related]
4. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
Geraci S; Kawamoto H; Caramanno G; Ruparelia N; Capodanno D; Brugaletta S; Gori T; Nef H; Sabate M; Mehilli J; Lesiak M; Naber C; Di Mario C; Capranzano P; Wiebe J; Araszkiewicz A; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Colombo A; Latib A
JACC Cardiovasc Interv; 2017 Mar; 10(6):560-568. PubMed ID: 28259663
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
[TBL] [Abstract][Full Text] [Related]
6. The Pt-Cr everolimus-eluting stent with bioabsorbable polymer in the treatment of patients with acute coronary syndromes. Results from the SYNERGY ACS registry.
de la Torre Hernandez JM; Moreno R; Gonzalo N; Rivera R; Linares JA; Veiga Fernandez G; Gomez Menchero A; Garcia Del Blanco B; Hernandez F; Benito Gonzalez T; Subinas A; Escaned J
Cardiovasc Revasc Med; 2019 Aug; 20(8):705-710. PubMed ID: 30414798
[TBL] [Abstract][Full Text] [Related]
7. A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY-IT study.
Ielasi A; Varricchio A; Campo G; Leoncini M; Cortese B; Vicinelli P; Brugaletta S; di Uccio FS; Latib A; Tespili M
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1129-1138. PubMed ID: 27774758
[TBL] [Abstract][Full Text] [Related]
8. Outcome of everolimus eluting bioabsorbable vascular scaffold (BVS) compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction (STEMI) - A comparative study.
Chakraborty R; Patra S; Banerjee S; Pande A; Khan A; Mandol PC; Ghosh D; De SK; Das SS; Nag R
Cardiovasc Revasc Med; 2016; 17(3):151-4. PubMed ID: 26905052
[TBL] [Abstract][Full Text] [Related]
9. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
10. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
[TBL] [Abstract][Full Text] [Related]
11. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry.
Wiebe J; Hoppmann P; Colleran R; Kufner S; Valeskini M; Cassese S; Schneider S; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
JACC Cardiovasc Interv; 2017 Jun; 10(12):1222-1229. PubMed ID: 28641842
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent - A Randomized Comparison Through 5 Years in Japan.
Kozuma K; Tanabe K; Hamazaki Y; Okamura T; Ando J; Ikari Y; Nakagawa Y; Kusano H; Ediebah D; Kimura T;
Circ J; 2020 Apr; 84(5):733-741. PubMed ID: 32213737
[TBL] [Abstract][Full Text] [Related]
14. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.
Lipinski MJ; Escarcega RO; Baker NC; Benn HA; Gaglia MA; Torguson R; Waksman R
JACC Cardiovasc Interv; 2016 Jan; 9(1):12-24. PubMed ID: 26762906
[TBL] [Abstract][Full Text] [Related]
15. Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R).
Nef HM; Wiebe J; Kastner J; Mehilli J; Muenzel T; Naber C; Neumann T; Richardt G; Schmermund A; Woehrle J; Zahn R; Riemer T; Achenbach S; Hamm CW
EuroIntervention; 2017 Dec; 13(11):1311-1318. PubMed ID: 28829745
[TBL] [Abstract][Full Text] [Related]
16. Procedural resources utilization and clinical outcomes with bioresorbable everolimus-eluting scaffolds and Pt-Cr everolimus-eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial.
de la Torre Hernandez JM; Garcia Camarero T; Lee DH; Sainz Laso F; Veiga Fernandez G; Pino T; Rubio S; Legarra P; Valdivia JR; Zueco Gil J
Catheter Cardiovasc Interv; 2017 Aug; 90(2):E25-E30. PubMed ID: 27807948
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of overlapping versus non-overlapping everolimus-eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov identifier: NCT02298413).
Tarantini G; Mojoli M; Masiero G; Cortese B; Loi B; Varricchio A; Gabrielli G; Durante A; Pasquetto G; Calabrò P; Gistri R; Tumminello G; Misuraca L; Pisano F; Ielasi A; Mazzarotto P; Coscarelli S; Lucci V; Moretti L; Nicolino A; Colombo A; Olivari Z; Fineschi M; Piraino D; Piatti L; Canosi U; Tellaroli P; Corrado D; Rovera C; Steffenino G;
Catheter Cardiovasc Interv; 2018 Jan; 91(1):E1-E16. PubMed ID: 28500737
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
Kereiakes DJ; Ellis SG; Kimura T; Abizaid A; Zhao W; Veldhof S; Vu MT; Zhang Z; Onuma Y; Chevalier B; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2017 Jan; 10(1):42-49. PubMed ID: 28017311
[TBL] [Abstract][Full Text] [Related]
19. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
